Avalo Therapeutics AVTX 深 沪
已收盘 11-13 16:00:00 美东时间
7.76
+0.060
+0.78%
华盛通- 最 高7.94
- 今 开7.73
- 成交量 97.42万股
- 最 低 7.445
- 昨 收 7.70
- 总市值 4.49亿
- 52周最高 24.27
- 市盈率 静 --
- 换手率 1.68%
- 52周最低 6.53
- 委 比 18.50%
- 总股本 5782.31万
- 历史最高 22032.00
- 量 比 0.38
- 振 幅 6.43%
- 历史最低 3.39
- 每 手 1
- 风险率 3.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 巴克莱维百济神州"超配"评级！目标价从415美元上调至446美元
今日重点评级关注：瑞银：维持Liberty Media"中性"评级，目标价从110美元升至1116美元；杰富瑞：维持伊诺维奥制药"买入"评级，目标价从3美元升至8美元
11-09 14:00
Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $20
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $22 to $20.
11-07 00:55
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics announced that its management will participate in two investor conferences: the Guggenheim Healthcare Innovation Conference on November 9, 2026, and the Stifel 2026 Healthcare Conference on November 10, 2026. Both events will feature fireside chats. The company is focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, with its lead candidate, abdakibart, advancing into a phase 3 p...
11-02 21:00
美股大行评级 | 潜在涨幅94.37%！摩根士丹利上调西部数据(WDC)目标价至668美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持西部数据"超配"评级，目标价从643美元升至668美元；摩根大通：维持西部数据"超配"评级，目标价从600美元升至650美元
10-26 12:30
Guggenheim Downgrades Avalo Therapeutics to Neutral
Guggenheim analyst Yatin Suneja downgrades Avalo Therapeutics (NASDAQ:AVTX) from Buy to Neutral.
10-23 23:05
Avalo Therapeutics shares are trading lower. AbbVie reported Phase 3 INTREPID results for Lutikizumab and the company's Adbakibart is a competing treatment for Hidradenitis Suppurativa.
Avalo Therapeutics shares are trading lower. AbbVie reported Phase 3 INTREPID results for Lutikizumab and the company's Adbakibart is a competing treatment for Hidradenitis Suppurativa.
10-23 00:27
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Fate Therapeutics appoints Jamie Harrell to its executive leadership team, leveraging his 25+ years of commercial experience in autoimmune therapies. Harrell will lead the commercial strategy for FT819 and FT839, advancing their development in autoimmune diseases like lupus nephritis and rheumatoid arthritis. His expertise in launching first-in-class therapies and expanding CAR T-cell access to community settings will support Fate's mission to tr...
10-12 11:00
Avalo Therapeutics To Present Abdakibart Data At EADV Congress 2026
Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vie...
09-23 19:07
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Avalo Therapeutics will present two late-breaking studies on its anti-IL-1β antibody, Abdakibart, for moderate to severe hidradenitis suppurativa (HS) at the EADV Congress 2026 in Vienna. The Phase 2 LOTUS trial's efficacy and safety data will be highlighted in an oral presentation by Dr. Martina Porter on October 1 and a poster presentation on September 30. Avalo is advancing Abdakibart into a Phase 3 program for HS, a chronic inflammatory skin ...
09-23 11:00
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics granted inducement equity awards to six new employees, including nonstatutory stock options for 78,000 shares with an exercise price of $19.34 per share. The options vest 25% after one year and monthly over the next 36 months, subject to continued employment. Avalo is advancing its anti-IL-1β monoclonal antibody, abdakibart, in a phase 3 trial for hidradenitis suppurativa and developing AVTX-010, a next-generation anti-IL-1β mA...
09-04 20:05
